Expansion and Enrichment of Gamma-Delta (γδ) T Cells from Apheresed Human Product
September 22nd, 2021
11.8K views
Presented is a protocol for the expansion of Gamma-Delta (γδ) T cell drug product. Lymphocytes are isolated by elutriation and γδ-enriched with zoledronic acid and interleukin-2. Alpha-beta T cells are depleted using a clinical-grade magnetic separation device. The γδ cells are co-cultured with K562-derived, artificial antigen-presenting cells and expanded.
Overview
This article presents a protocol for the expansion of Gamma-Delta (γδ) T cells, which are known for their cytotoxic activity against various cancers, including acute myeloid leukemia. The method described allows for a significant increase in γδ T cell numbers, making them more accessible for therapeutic applications.
Key Study Components
Area of Science
- Immunology
- Cancer Therapy
- Cell Therapy
Background
- Gamma-Delta T cells are rare in the bloodstream, especially in cancer patients.
- These cells have potential in reducing leukemia recurrence and improving survival rates.
- The proposed method enables over 200,000-fold expansion of γδ T cells.
- It can be adapted for various enrichment methods and additional manipulations.
Purpose of Study
- To develop a reliable protocol for expanding γδ T cells for therapeutic use.
- To enhance the availability of these cells for clinical applications.
- To demonstrate the feasibility of the method in a laboratory setting.
Methods Used
- Isolation of lymphocytes via elutriation.
- Enrichment of γδ T cells using zoledronic acid and interleukin-2.
- Depletion of alpha-beta T cells using magnetic separation.
- Co-culture of γδ T cells with artificial antigen-presenting cells (AAPCs).
Main Results
- Achieved a highly pure γδ T cell product suitable for therapy.
- Demonstrated successful cell expansion in a closed bioreactor system.
- Maintained high cell viability throughout the process.
- Established a protocol that can be scaled for clinical use.
Conclusions
- The method significantly enhances the utility of γδ T cells for cancer and autoimmune diseases.
- It provides a framework for future research and clinical applications.
- Further adaptations could improve efficiency and effectiveness of cell expansion.
Frequently Asked Questions
What are Gamma-Delta T cells?
Gamma-Delta T cells are a subset of T cells that play a crucial role in the immune response, particularly against cancer.
How does the expansion protocol work?
The protocol involves isolating lymphocytes, enriching γδ T cells, depleting alpha-beta T cells, and co-culturing with AAPCs.
What is the significance of γδ T cells in cancer therapy?
They have potent cytotoxic effects against various cancer types, making them promising candidates for immunotherapy.
How long does the expansion process take?
The entire process can be completed in approximately 10 days.
Can this method be adapted for other cell types?
Yes, the method can be modified to expand different types of T cells or other immune cells.
What are the potential applications of expanded γδ T cells?
They can be used in cancer treatment, autoimmune diseases, and possibly other therapeutic areas.
Executive Industry Relevance
Expanding rare Gamma-Delta T cells from apheresis products addresses a critical bottleneck in allogeneic cell therapy manufacturing, enabling therapeutically relevant doses for oncology indications. The protocol supports pipeline advancement by generating highly pure, cytotoxic effector cells with minimal alpha-beta T cell contamination, reducing graft-versus-host risk. This positions the method as a scalable solution for off-the-shelf immunotherapy development in hematologic malignancies and solid tumors.
Strategic Applications in Biopharma R&D
Early Discovery & Target Validation
- Scientific Value: Enables functional validation of Gamma-Delta T cell antitumor activity through expansion of cytotoxic effectors from primary human sources.
- Operational Value: Provides a reproducible system to interrogate MHC-independent antigen recognition mechanisms in preclinical models.
Screening & Assay Development
- Scientific Value: Generates standardized, high-purity effector cells for screening immunomodulatory compounds or bispecific engagers.
- Operational Value: Delivers consistent cell doses and viability metrics (>95%) essential for assay standardization and inter-laboratory comparability.
Translational & Preclinical Research
- Scientific Value: Supports mechanistic de-risking by producing clinically relevant cell doses to evaluate in vivo persistence and tumor infiltration in AML xenograft models.
- Operational Value: Enables process development studies under GMP-like conditions using clinical-grade magnetic separation and closed bioreactor systems.
Pipeline & Workflow Integration
The method integrates into the discovery-to-preclinical continuum by enabling target validation, assay preparation, and mechanistic studies using expanded effector cells.
- Discovery Biology: Supports hypothesis testing of Gamma-Delta T cell-mediated tumor lysis and cytokine secretion profiles.
- Screening: Delivers assay-ready cells with consistent expansion kinetics for compound screening and immunomodulator evaluation.
- Analytics: Provides quantitative outputs including fold expansion (>229,000), viability, and purity metrics for process monitoring and decision-making.
- Translational Research: Bridges discovery to preclinical validation by generating doses sufficient for efficacy and safety studies in disease-relevant models.
- Enterprise Reuse: Establishes a modular platform adaptable to donor variability and enrichment strategy optimization across cell therapy programs.
Operational & Enterprise Impact
- Scientific Value: Predictive confidence in target engagement through MHC-independent cytotoxicity and reduced alloreactivity via alpha-beta T cell depletion.
- Operational Value: Standardized expansion workflow using clinical-grade instruments and defined culture conditions ensures reproducibility across batches.
- Strategic Value: Enables risk-adjusted go/no-go decisions by delivering sufficient cell numbers for preclinical efficacy testing and IND-enabling studies.
- Portfolio Impact: Facilitates risk-adjusted prioritization of Gamma-Delta T cell programs by mitigating manufacturing feasibility concerns in allogeneic settings.
Implementation Considerations
- Requires expertise in cell therapy manufacturing, flow cytometry, and closed-system bioreactor operations.
- Dependent on access to counterflow centrifugation elutriation devices and clinical-grade magnetic cell separation systems.
- Necessitates standardization of zoledronic acid and IL-2 dosing across donor lots to ensure consistent preferential expansion.
- Requires adaptation of artificial antigen-presenting cell (aAPC) irradiation and co-culture ratios for scalability.
- Practical limitations include donor variability in lymphocyte yield and natural killer cell content impacting expansion efficiency.
Biopharma FAQs
Why does elutriation precede Gamma-Delta T cell expansion in apheresis products?
Elutriation isolates lymphocytes by size and density to enrich the starting population, improving the efficiency of subsequent Gamma-Delta T cell activation and expansion.
How does zoledronic acid contribute to preferential Gamma-Delta T cell expansion?
Zoledronic acid activates Gamma-Delta T cells in an MHC-independent manner, driving their proliferation when combined with interleukin-2 during the initial expansion phase.
What is the purpose of TCR alpha-beta depletion using magnetic separation?
Magnetic depletion removes contaminating alpha-beta T cells to reduce graft-versus-host disease risk and enhance the purity of the Gamma-Delta T cell product.
Why are artificial antigen-presenting cells used in the second expansion phase?
Engineered aAPCs provide co-stimulatory signals (CD3, CD28, 41BBL) and cytokines (IL-15RA) to sustain Gamma-Delta T cell expansion and achieve high fold increases.
What analytical methods confirm product purity and release criteria?
Flow cytometry and cell surface staining verify Gamma-Delta T cell identity, assess alpha-beta T cell depletion (<1%), and measure viability (>95%) and natural killer cell content (<35%) for release testing.
Chapters in this video
0:04
Introduction
1:29
Lymphocyte Isolation and Alpha-beta (αβ) T Cell Depletion
6:16
Co-culture with Artificial Antigen-Presenting Cells (aAPCs) and Cell Harvest
9:22
Results: Characterization and Optimization of the γδ T Cell Expansion Process
11:21
Conclusion
